| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8230179 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 7 Pages |
Abstract
Bevacizumab can be safely combined with hypofractionated radiotherapy and capecitabine as a preoperative radiochemotherapy regimen for patients with rectal cancer. The high pathologic complete response rates urges the testing of bevacizumab in randomized studies.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Michael I. M.D., Alexandra M.D., Pelagia M.D., Nikolaos M.D., Michael M.D., George M.D., Pelagia A. M.D., Kostantinos M.D., Efthimios M.D.,